Mometasone – synthetic glucocorticosteroid , which has anti-inflammatory, antipruritic and antiexudativ action. GCS induce protein excretion-inhibiting signs of low t , and collectively known lipocortin which control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.
After 8 hours after application on intact skin (without occlusive dressings) detected in the systemic circulation of about 0.4% of the formulation.
Inflammation and itching at dermatoses, measurable glucocorticosteroid therapy.
- Hypersensitivity to any component of the formulation or to the glucocorticosteroid drugs.
- Rosacea, perioral dermatitis.
- Bacterial, viral (Herpes simplex, chicken pox, Herpes zoster), or a fungal infection of the skin.
- Tuberculosis, syphilis.
- Post-vaccination reactions.
- Children up to age 6 months.
- Pregnancy (treatment of large areas of skin, long-term treatment).
- Lactation (used in large doses and / or for a long time).With careful
application on the skin and in the folds, the use of occlusive dressings, as well as the treatment of large areas of skin and / or long-term treatment (particularly in children).
Use during pregnancy and lactation
The safety of signs of low t during pregnancy and lactation has not been studied.
Corticosteroids cross the placental barrier. Avoid long-term treatment and the use of large doses during pregnancy due to the risk of negative impact on fetal development.
Corticosteroids are excreted in breast milk. In the case where the use of corticosteroids expected at high doses and / or for a long time, discontinue breastfeeding.
Dosage and administration:
A thin layer is applied to the affected skin once daily. The duration of treatment is determined by its efficiency, as well as the tolerance of the patient, presence and severity of side effects.
Rarely – skin irritation and dryness, burning sensation, pruritus, folliculitis, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, the accession of secondary infection, signs of skin atrophy, striae, miliaria. Less than 1% of cases – the formation of papules, pustules.
In the application for a long time and / or to treat large areas of skin, or with the use of occlusive dressings, especially in children and adolescents, may experience side effects characteristic of glucocorticosteroids systemic effects, including adrenal insufficiency and Cushing’s syndrome.
Overdose Symptoms: inhibition of the function of the hypothalamic-pituitary-adrenal system, including secondary adrenal insufficiency. Treatment: symptomatic, if necessary – correction of electrolyte imbalance, removal of the drug (for long-term treatment – phasing out).
when applied to large areas of the skin for a long time, especially when using occlusive dressings may develop systemic effects of corticosteroids. In view of this, patients should be observed for signs of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing’s syndrome.
Propylene glycol, which is part of the preparation, may cause irritation at the site of application. In such cases, discontinue using the and appropriate treatment.
It should be borne in mind that corticosteroids are able to change some of the manifestations of skin diseases that can complicate diagnosis. In addition, the use of corticosteroids may be the cause of the delay wound healing.
In long-term treatment of sudden cessation of therapy can lead to rebound syndrome, which manifests itself in the form of dermatitis with intense redness and burning sensation. So after prolonged treatment abolition of the drug should be made gradually, for example, going to the intermittent regimen before its full stop.
- Paediatric use The safety and efficacy signs of low t when applied topically in children during the period of more than 6 weeks, has not been studied . due to the fact that in children the value of the surface area ratio and body weight greater than that of adults, children are at greater risk of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing’s syndrome in the application of any of local action. Long-term treatment of children can lead to violations of their growth and development. children should receive the minimum dose sufficient to achieve the effect. for children from 6 months to 2 years of treatment should not exceed 5 days.